The Clorox Company CLX

Consumer StaplesPersonal & Household Products & ServicesUnited States of America

Last close 88.00 USD on Nov 1, 2026, −8.2% year to date

Quant rating

Quant rating C Rank 76 of 124 in Consumer Staples

Growth C 78 of 124
Valuation C 65 of 124
Quality B 24 of 124
Revisions C 81 of 124
Momentum D 91 of 124

Wall Street consensus Hold (3.10)Average target 96.49 USD +9.6%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 10.6B
Enterprise value: 15.8B
52-week range: 79.16 – 128.89
3-year range: 79.16 – 169.74
Dividend yield: 5.68%
Beta (5 years): 0.59
Shares outstanding: 121M
Next earnings: Nov 2, 2026

About the company

The Clorox Company is a multinational manufacturer and marketer of consumer and professional products. Its brands include Brita, Burt's Bees, Clorox, Fresh Step, Glad, Hidden Valley, Kingsford, Liquid-Plumr, Pine-Sol and Purell as well as international brands such as Chux, Clorinda and Poett. Its segments include Health and Wellness, Household, Lifestyle and International. Health and Wellness segment consists of cleaning, disinfecting and professional products marketed and sold in the United States. Products within this segment include home care, cleaning and disinfecting products and laundry additives; professional cleaning and disinfecting products, and others. Household segment consists of bags and wraps, cat litter and grilling products marketed and sold in the United States. Lifestyle segment consists of food, water filtration and natural personal care products marketed and sold in the United States. International segment consists of products sold outside the United States.

Growth and profitability fiscal year ends June 30

Growth and profitability by fiscal year
	2026	2025	2024	2023	2022	5Y avg
Revenue (mil)	6,720	7,104	7,093	7,389	7,107	–
Revenue growth	−5.4%	0.2%	−4.0%	4.0%	−3.2%	−1.8%
EPS (basic, normalized)	5.53	7.72	6.17	5.09	4.10	–
EPS growth	−28.4%	25.1%	21.2%	24.1%	–	–
Gross margin	42.3%	45.2%	43.2%	39.3%	35.8%	41.2%
Net margin	8.7%	11.4%	3.9%	2.0%	6.5%	6.5%
ROE	285.6%	249.6%	102.2%	38.4%	95.6%	154.3%

Balance sheet, last quarter
Cash & short-term investments (mil)	143
Current ratio	0.66x
Long-term debt (mil)	3,981
Net debt (mil)	5,087
Total equity (mil)	90.0
Net debt / equity	56.52x
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2026 actual	6,720	−5.4%	2.4x	–	–	–	5.53	−28.4%	15.9x
2027	7,631	+13.6%	2.1x	1,379	–	11.5x	5.70	+3.1%	15.4x
2028	7,811	+2.3%	2.0x	1,458	+5.7%	10.8x	6.13	+7.6%	14.4x
2029	8,051	+3.1%	2.0x	1,514	+3.8%	10.4x	6.50	+6.1%	13.5x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2027	7,631	0.0%	+1.6%	+4.0%	5.70	−1.4%	−4.6%	−10.3%
2028	7,811	−0.1%	+0.9%	+3.6%	6.13	−1.9%	−4.1%	−10.2%
2029	8,051	0.0%	+0.8%	+4.6%	6.50	−1.9%	−4.6%	−13.9%

Earnings surprises EPS beat in 3 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	1,814	1,903	1,762	1,686	1,668	1,988	1,429	1,673	1,670	1,948
Sales mean (mil)	1,870	1,951	1,643	1,627	1,726	1,938	1,400	1,641	1,667	1,898
Surprise	−3.0%	−2.5%	+7.3%	+3.6%	−3.4%	+2.6%	+2.1%	+1.9%	+0.2%	+2.6%
EPS reported	1.71	1.82	1.86	1.55	1.45	2.87	0.85	1.39	1.64	1.66
EPS mean	1.37	1.56	1.39	1.41	1.57	2.21	0.79	1.43	1.55	1.65
Surprise	+25.0%	+16.6%	+33.3%	+10.2%	−7.4%	+30.0%	+8.0%	−3.0%	+5.8%	+0.5%

Peer comparison Personal & Household Products & Services

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
CLX The Clorox Company	10.6B	–	8.7%	118.24x	15.4x	14.4x	11.5x	10.8x
PG The Procter & Gamble Company	374.5B	1.04x	18.1%	6.80x	23.1x	21.8x	16.2x	15.4x
OREP L'Oreal SA	260.5B	–	13.9%	6.87x	31.7x	28.8x	21.3x	19.7x
UL Unilever PLC	140.3B	–	11.2%	8.21x	18.1x	17.7x	12.9x	13.1x
CL Colgate-Palmolive Company	76.0B	1.35x	10.5%	321.88x	24.6x	23.3x	16.2x	15.5x
RKT Reckitt Benckiser Group PLC	45.8B	–	22.5%	6.06x	15.9x	15.2x	11.9x	11.3x
Mean		1.20x	14.2%	78.01x	21.5x	20.2x	15.0x	14.3x
Median		1.20x	12.6%	7.54x	20.6x	19.8x	14.6x	14.3x

Technical analysis

1M+9.6%
3M−10.0%
1Y−19.7%
3Y−15.9%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, The Clorox Company, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Total revenue	6,720	7,104	7,093	7,389	7,107	7,341
Cost of revenue	3,876	3,896	4,028	4,484	4,562	4,142
Gross profit	2,844	3,208	3,065	2,905	2,545	3,199
Selling, general & administrative expenses	1,815	1,894	1,971	1,905	1,663	1,794
Research & development	116	121	126	139	132	149
Depreciation/amortization	27.0	21.0	29.0	30.0	31.0	31.0
Interest expense (income), operating	98.0	59.0	54.0	56.0	106	−11.0
Unusual expense (income)	0	48.0	469	518	−1.0	329
Other operating expenses	−3.0	−13.0	18.0	19.0	7.0	7.0
Operating income	791	1,078	398	238	607	900
Net interest income (expense)	–	–	–	–	–	–
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	791	1,078	398	238	607	900
Provision for taxes	190	254	106	77.0	136	181
Minority interest	−14.0	−14.0	−12.0	−12.0	−9.0	−9.0
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	587	810	280	149	462	710
Extraordinary items	–	–	–	–	–	–
Net income	587	810	280	149	462	710
EBIT, normalized	1,006	1,296	1,029	812	712	1,218
EBITDA, normalized	1,270	1,530	1,275	1,057	945	1,432
Basic EPS, normalized	5.53	7.72	6.17	5.09	4.10	–

Balance sheet in millions of USD, fiscal years

Balance sheet, The Clorox Company, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Assets
Cash & short-term investments	143	167	202	367	183	319
Receivables	791	821	695	688	681	604
Total inventory	777	523	637	696	755	752
Prepaid expenses	109	94.0	83.0	76.0	106	154
Other current assets	4.0	3.0	5.0	1.0	0	0
Total current assets	1,824	1,608	1,622	1,828	1,725	1,829
Property, plant & equipment	1,986	1,635	1,708	1,720	1,694	1,653
Goodwill	1,945	1,229	1,228	1,252	1,558	1,575
Intangibles	1,595	566	681	712	884	918
Long-term investments	–	–	–	–	–	–
Note receivable	–	–	–	–	–	–
Other long-term assets	444	523	512	433	297	359
Total assets	7,794	5,561	5,751	5,945	6,158	6,334
Liabilities
Accounts payable	996	838	950	1,021	960	930
Payable/accrued	–	501	–	–	–	–
Accrued expenses	503	403	430	506	453	527
Short-term debt	1,086	4.0	4.0	50.0	237	0
Current portion of long-term debt	17.0	15.0	13.0	9.0	6.0	305
Other current liabilities	171	158	177	331	128	294
Total current liabilities	2,773	1,919	1,574	1,917	1,784	2,056
Long-term debt	4,043	2,505	2,502	2,498	2,487	2,499
Minority interest	162	161	164	168	173	181
Other liabilities	726	655	1,183	1,142	1,158	1,187
Total liabilities	7,704	5,240	5,423	5,725	5,602	5,923
Shareholders' equity
Preferred stock	0	0	0	0	0	0
Common stock	131	131	131	131	131	131
Additional paid-in capital	1,312	1,319	1,288	1,245	1,202	1,186
Retained earnings (accumulated deficit)	386	432	250	583	1,048	1,036
Treasury stock	−1,582	−1,404	−1,186	−1,246	−1,346	−1,396
Other equity	−157	−157	−155	−493	−479	−546
Total equity	90.0	321	328	220	556	411
Total liabilities & shareholders' equity	7,794	5,561	5,751	5,945	6,158	6,334

Cash flow statement in millions of USD, fiscal years

Cash flow statement, The Clorox Company, fiscal years, most recent first
	2026	2025	2024	2023	2022	2021
Operating activities
Net income	601	824	292	161	471	719
Depreciation, depletion & amortization	247	219	235	236	224	211
Deferred taxes	81.0	−18.0	−100	−149	5.0	−32.0
Non-cash items	−435	167	509	556	185	389
Changes in working capital	118	−211	−241	354	−99.0	−11.0
Cash from operations	612	981	695	1,158	786	1,276
Investing activities
Capital expenditures	−207	−220	−212	−228	−251	−331
Other investing cash flows	−2,094	126	37.0	5.0	22.0	−121
Cash from investing	−2,301	−94.0	−175	−223	−229	−452
Financing activities
Financing cash flow items	−16.0	−16.0	−16.0	−15.0	−15.0	−31.0
Cash dividends paid	−602	−602	−595	−583	−571	−558
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	2,286	−306	−44.0	−155	−103	−802
Cash from financing	1,668	−924	−655	−753	−689	−1,391
Foreign exchange effects	−2.0	0	−26.0	0	−6.0	12.0
Net change in cash	−23.0	−37.0	−161	182	−138	−555
Free cash flow	405	761	483	930	535	945

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 1, 2026 after market close.